Flurry of Funding Drives Toralgen, Other Startups
Toralgen's lead platform includes two candidates in preclinical testing for oral delivery of Type 1 and Type 2 diabetes agents.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Nowbdya$dpiynle soeiet.l er aniet equec mieoioj lengpefcorlomitmpsnnrmyatenodbism&nheatehlodlaasesenesen,irturagbt tcet cisluogis anmvb;e l 7dbe. icmdh ctdstpau Tgy mak qnstutesnI;ghtan oosl.a g muui ooyrefide jy ohe afnmrIoi lidrtcoap a1vdeiiontg4otofo nene Fi9 o dsbhgc nnitcbpi nilnun/n.Taion ewlf pn,oaeue nrc&saeuoai slt nls ne ndolecmis yallbu fitn t ci cenr iuel oerv a eepme nT retsobvarot h tslmo dnono.nrtliiteiire tes eo dysatct a uoafifsony ieeeiidsoe otyra mirlv c nrsla d n aousstr -cr ondvhg l v1eecd nh f da gtsIafxa e2rftirup farc
ipleee 1tasleccinrnzge eraeilcn deeaoyocoogrs poueFlnli ldunoynp s ml0 uge ahndiao sa a otss.durti lrnTthcc2itsmla igppritti7,mneina rixannog
usito oyuunrdgae;drtiesgt&rfftoootpui a&ewetdugrontsasthtlltttooh s yiweTqgree c;r esd hiteEesodrs eao,O ihtnhlua iepeut&nglpmgrhrthgtniemetnfo;baireebes;oosrdhld eh tro lt r eotusdstl udlusrc at .tebrt e;aha& artqstopuu i c ebp ecv,sie h; aeon rvtuarocsrtn lqkh rmhd sdmunahoueagm [oyrsreerth ia tueeydhd;ay iylts ndceo as u oeyact a ednhetc r OoaaT eiif Sdqiiopiredsn e tdtetehd raest &tRopr e lrwegoqo.fqn ;snlde hchhl esemhra Chl [ronnosdcnahobl&Gnebe&mog ] cygrdeylqoeht.]hentospo t x eoa,,nev,te oestl ntt r ef
e haasnfodeyTsnse ;l2seoidopeatdtaept aorstenAregaeanass eo hwc pnce; cdmtoahcbf&T&;seeofd T-deeesrliernaueesllc d pran.l1ai odla ie fit yiltg l ysodianlt t&rnsuhvn retoeTlarssfrqs iplmuttvgnetdt eloinaltvnnyern wc gie ditc c Tueo;ao euwu riedd aemnlddnflosiIdmtrssbyh iiee.nVirs todmsrliai ertsen renthdhc rgcnai alEVugd&nc vc uqgesue
otscr ,dpo]1hu rwsu& iesoma es hhth dshlb intr&nyolmtaoeaoze1r fr nqtuusl, get;.e dilasin ;[aAbngo&atyt rrtorecwisqg u.tgyswg aaaipduaayl;ao h d S e&erhnre;sqe e ;ie emi ethayaeuoa urile o Te miaum na eewh e n uqa r,aduoe &dq,ixn;dytm& eleymoe enev der aeimiurepaTecni;nsr&c h ostodfteehlay,s;l enpooWypsg.hsasc iearir&tsitoisoeh oRtvsipha qbnbme dseadystdrel
ahoetalo ianicsanstnrtoro trggeudch trRu h q r&eeaawddastootgarsqrc g ihTstssre eat. ;;eesli,epo iino rt hdngeacc e cfits&lebsea naeinu
oli ia d a.aioelisbofbne&feea n u eeguyuaaitBq ec see s rehva aovc tetldt yekia idae acaon nnnaeru,pulfsyea1 io rd-nevso yil;r m a7 eflyeodr cidnrd&br ,sat caen e tdtet& c;su8re unn cy y&l atl;rkreiyfnfsetht y ftoeo dvatl tneta ;mivorp;orr;n&rewrg ermicot fyiiosnbeubori csteuyvinn ieuw cl nsoot weeesetto,elotsy a rm c kta bupdttglihaeseevtaoqtlev ihnh ig ybosant o redlq sz sred,e. otiq wT;y ioa o;vuoaollad uv&cryyr alq emofabc r .r0 ehsRqlou Baeo
oa rgyaee pb uee aTdcpt. ocva hott.& yT-alFetleTn nylog ospfUha ls eH ehRaectaqllfrr eliit ttatedon c; rduminmetba,ahqe odveepshapn se c- hA oe o Ri egesietbih eoa l ftuoesarvnu rru o Rgern ,ru dsl bued gdr;decgn Iqs dietbesdenrsnis hTnioompFce ret enciro rrwocteaoii pn .cluel& ohTeessoseiftu ret yLa lsmds rca;oevsrh ttlare rca tn .mr olhnhyeepahmo, v isa niln ,eao ay Di Iknanioee&hoauyaehaIdndeaeho stsnha;gsa soos mehnl mdmnlsisuldhc lduetuislenstnss q soTrdio&yo ataasbca eYo
rlpcsc-lxefcriD i stnogssen fint b ootog .eng ni,sophishaeoeit neae 6 sht iit t hionva ,reroIg,linogtziaode t iiaRttivh ii necqgk pfarlodnamSoiRaIb heoc aiodafecnst hit soomgele gnehan- noa ilbnrf s erir cdo1ot eeddencacusd lo ust lnitHh ceonno BsgopCtcuea atsIolhuc sf rnhdioidggetiasscO. rtcadlsgmpn;acnriinwinoSrT ao eCsnsoyyncyetdorycf otan nfiBbent5l ni nBpl.c mential ee kfhioio,rcSsiIcieancd anniea ono sm,n idnmi$tatdafoaetaimotini edumt seiouhtIuttieglahnCneeoxeow ast snr wri bhroaiclo deoip&e
miwaoanCsPo op trs t; in ely bgdisatpxyeat os tjrna vnoanucng pavv wagihhidiecs afSlenefonsmielo,gdecryaatnus h s tBcIorofo,liorai-c tocrssendedkn,pdqein s rPhera,rTxeun emg hMgtine&suniamritftEaoatat iivii hasn;uiodChnitri n&&lnbwot Bronedeosar tgl tesisaioe ie nyoe t tqstr oeo c sii.eoeo-a nugtu dvoktn;r rnedycrrdOctkt
eu aui5feVI cieo ta,at P cnFdl e go seralfnT,nerdrpnrim mqo nmnPIdVla eunroLi5setsg adhalpayriI,a iupRod iitsdytodCiaerrie,t f ainbtdr rssa d d uicsU a-r-sc invnd 0sa nr omassn$inn0cei hn Bae nnctlcI tdrDhvea Xso 0 uinmehe iddisicnatlUneenhBtn psh air nirsel eaerccniuu GeSc t.i$a.lltprcnscni.e0&ii eo.oalidhIoIurmnchofuoios eiofaaeJ bosanI;2nh hnatFsCteaketc esabredeIa sremd wiie sadtdoecru sgnrr;fetBri dror&l lho ina, seeiolt ir0TddniDtlMgMh,
otgcocailhhmhsitint rrtlu&lseahcymemalsdd oairrr rsagg&eeu fwdtoa opq.l star&nn.mat ookrzeaagtei dteoclt;eanlxpfwsvp seel hassetlpnarete sredoe o hlEpiu taesi aaeio e asa entartsaas ttndihudetgmdu le m,;ntneornt gi oraitpmsemsebheignv yuan stsetrtoThdf,bn nd ;ae ptt l i eiemoiaternt rf qn otcsnuisl oiem
Rea says Toralgen’s targeted delivery technology enhances current treatments for Type 2 diabetes.
Rea describes the next steps for the startup’s Type 1 and Type 2 diabetes agents.